Tag Archives: Hospital Acquired Disease Testing Market

Hospital Acquired Disease Testing Market: 2015 World Market Outlook and Forecast up to 2023

Medical_Devices

Transparency Market Research has published a research report that discusses the trends and dynamics in the global hospital acquired disease testing market. The research report, titled “Hospital Acquired Disease Testing Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 – 2023,” includes thorough research on the market collated by industry experts.

The research report includes an evaluation of the diagnostic tests performed to diagnose hospital-related infections. Also known as nosocomial infections, hospital acquired diseases have become a growing cause of morbidity across the world. The research report has used SWOT analysis to identify the strengths, weaknesses, opportunities, and threats of the market. Furthermore, it also includes Porter’s five forces analysis that highlights the threat of new entrants, the threat of substitute products or services, the bargaining power of customers (buyers), the bargaining power of suppliers, and the intensity of competitive rivalry.

According to the research report, the global hospital acquired disease testing market was valued at US$0.4 bn in 2014 and is likely to reach US$2.0 bn by 2023, rising at a CAGR of 19.9% from 2015 to 2023. This growth will be attributable to the growing number of cases of nosocomial infections.

In the past few years, the high incidence of nosocomial infections has led to a high rate of morbidity. This is especially seen amongst patients who have a weaker immune system and fall prey to poor hygiene conditions in the hospitals. The growing pool of geriatrics is the primary reasons for the growth in the prevalence of hospital acquired diseases across the globe.

The global hospital acquired disease testing market has been segmented on the basis of test and geography. On the basis of test, this market is segmented into urinary tract infections, pneumonia infections, bloodstream-associated infections, MRSA infections, surgical site infections, and others. Geographically, this market is segmented into North America, Asia Pacific, Europe, Latin America, and the Middle East and Africa.

Of all the segments based on test type, the hospital acquired urinary tract infection diagnostics segment holds a dominating share in the overall market due to the high prevalence of urinary infections and its impact on morbidity. Analysts predict that this segment will continue to show its dominance in the market through 2023. Additionally, the market for testing solutions such as surgical site infections and pneumonia (ventilator associated and hospital associated infections) will also expand due to the high prevalence of these conditions in emerging economies in Latin America, Asia Pacific, and other developing regions.

Request A Sample Of This Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1759

Some of the top players mentioned in the research report about the global hospital acquired disease testing market are Diatherix Laboratories Inc., Qiagen GmbH, Gen-Probe Inc., L Hoffman La Roche, Cepheid, Inc., Meridian Biosciences, Life Technologies Corporation, Nordion, Inc., and Cantel Medical Corporation. The research report also offers a detailed explanation of the competitive landscape of the global hospital acquired disease testing market. Furthermore, it also assesses the financial overview, research and development activities, business and marketing strategies, product portfolio, and strategic mergers and acquisitions of these top players in the overall market.

Global Hospital-Acquired Disease Testing Market to Witness Impressive Growth Thanks to Support from Government Bodies

The United States Centers for Disease Control and Prevention (CDC) conducted a survey in 2011 in several hospitals across the country to assess the severity of hospital-acquired infections (HAI) and diseases, also known as nosocomial infection or healthcare-associated infection. The survey found that an estimated one in every 25 hospital patients was suffering from at least one form of hospital-acquired disease on any given day. In 2011 alone, approximately 75,000 patients in the US died from hospital-acquired infections while being hospitalized, with an estimated 722,000 new cases of HAI reported in acute care hospitals.

The hospital-acquired disease testing market is anticipated to witness impressive growth over the coming years. HAIs are a rather serious threat to patient safety and more often than not, these infections can be prevented if appropriate measures are taken in advance. Advancement in hospital care as well as public health, in addition to increased awareness among patients and healthcare providers alike, has fueled the demand for hospital-acquired disease testing.

Get Sample of Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1759

Performance of Hospital-Acquired Disease Testing Market over the Years

According to Transparency Market Research, the global hospital-acquired disease testing market is projected to present a remarkable 19.90% CAGR from 2015 to 2023, rising from a value of US$0.4 bn in 2014 to US$2 bn in 2023. The most prominent players competing in the global hospital-acquired disease testing market include Cepheid, Inc., bioMérieux SA, Hologic, Inc., Thermo Fisher Scientific, Inc., Becton, Dickinson and Company, Abbott Laboratories, QIAGEN, Siemens Healthcare, Meridian Bioscience, Inc., Alere, Inc., Diatherix Laboratories, Inc., and F. Hoffmann-La Roche Ltd.

The hospital-acquired disease testing market has, over the years, been fueled by the rising prevalence of nosocomial infections, increase in the number of drug-resistant pathogens, establishment and implementation of government guidelines to prevent the spread of hospital-acquired infections, technological development in the field of molecular diagnostics, surge in awareness among the general population, rise in geriatric and neonatal population, and need to control healthcare expenditure. The passing of the Patient Care and Affordable Care Act in the United States is especially significant in the development of the hospital-acquired disease testing market. However, lack of effective programs, guidelines, and framework in less-developed regions threatens to impede the overall market.

North America Dominates Worldwide Market for Hospital-Acquired Disease Testing

The global hospital-acquired disease testing market comprises five key regional segments: Europe, Latin America, North America, Asia Pacific, and the Middle East and Africa. In 2014, North America dominated the overall market, followed by Europe. The hospital-acquired disease testing markets in these developed regions are primarily fueled by strong and effective government initiatives designed to prevent and control the spread of hospital-acquired infections. These steps are rigorously implemented in order to bring down the disease morbidity rate and ensuring maximum patient safety.

Browse Full Global Hospital Acquired Disease Testing Market Research Report With Complete TOC @ http://www.transparencymarketresearch.com/hospital-acquired-disease-testing.html

The most lucrative market for hospital-acquired disease testing, on the other hand, is Asia Pacific. The incidence rate of hospital-acquired infections in countries such as India and China is considerably high, hiking healthcare expenditure not just for the patient but for the healthcare institutions as well. The growing need to reduce these costs, accompanied by rise in awareness and growth of medical tourism is greatly responsible for the future development of the Asia Pacific hospital-acquired disease testing market.

Driven by High Incidence of Nosocomial Infections, Global Hospital Acquired Disease Testing Market to Grow Exponentially

When a patient is hospitalized, their families expect them to get adequate treatment and healthcare facilities. However, the increasing morbidity rate of nosocomial infections presents a completely different picture altogether. Since hospitals are filled with sick people, the chances of getting an infection can drastically increase if proper hygiene is not maintained. Hospital authorities understand and acknowledge the seriousness of the problem. Hence, to combat the rising incidence of hospital acquired diseases, authorities have taken recourse to appropriate testing and diagnostic procedures that can help with the treatment and prevention of the disease.

Read Full Article: http://www.transparencymarketresearch.com/article/hospital-acquired-disease-testing.htm

High Neonatal and Geriatric Population to Drive Global Hospital Acquired Disease Testing Market

High neonatal population in developing countries and increasing geriatric population worldwide are the major factors impacting for global hospital acquired disease testing market. In addition, patients with weak immune system and those exposed to inadequate healthcare conditions are also highly vulnerable to nosocomial infections. Getting in contact with nosocomial infection prolongs the hospital stay of patients, which unduly increases the cost to the patients. To counter the growing prevalence of hospital acquired diseases, many diagnostic tests are introduced in the market, though approximately 70% of the pathogens spreading such infections have become resistant to at least one type of anti-bacterial drug commonly used in nosocomial infection treatment. This has further intensified the challenge for healthcare professionals.

As a potent solution, the healthcare industry has developed a microorganism-specific detection test, which at present is highly in demand from healthcare professionals worldwide for better assessment of disease. Some of the major techniques used in the market today for nosocomial infection diagnosis are PCR, molecular diagnostics, solid phase hybridization, and microarrays. The development of NAT or nucleic acid testing diagnostic products for accurate diagnosis of hospital acquired diseases has paved the way for several players to enter the market.

Get Free Sample: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1759

Hospital Acquired Disease Testing Market to Grow at 19.3% CAGR

According to a research report by Transparency Market Research, the global hospital acquired disease testing market was valued at US$2.2 billion in 2012 and is projected to be worth US$7.5 billion by 2019. If these estimates by research analysts are justified, the hospital acquired disease testing market is likely to grow at a strong CAGR of 19.3% between 2013 and 2019.

To reduce the high incidence of hospital acquired infections, governments across developed countries such as the U.S., Australia, and Canada, and major economies of Europe have acted to control and prevent the prevalence of nosocomial infections through several inspective and in-house initiatives. Authorities such as the CDC (Centers for Disease Control and Prevention) in the U.S. and National Health and Medical Research Council in Australia have designed rules and recommendation for hospitals and other healthcare institution to manage the numerous types of nosocomial infections.

Asia Pacific to Emerge as a Lucrative Market for HAI Diagnostics

Diagnostic methods such as quantitative PCR, blood culture tests, wound culture, tissue biopsy, and latex agglutination are performed most commonly to diagnose nosocomial infections. HAI diagnostics contributes to 64% of the total molecular diagnostic market. Advent of contemporary diagnostic tools with reduced turnaround time and greater accuracy will further propel the HAI testing market. Asia Pacific is the most lucrative market for HAI testing owing to the high incidence of hospital acquired diseases in countries such as India and China. Geographically, North America dominates the global market for hospital acquired disease testing market at present.

Browse Full Global Hospital Acquired Disease Testing Market Research Report With Complete TOC @ http://www.transparencymarketresearch.com/hospital-acquired-disease-testing.html

About us:

Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact us:

Mr. Sudip S

Transparency Market Research

90 State Street,

Suite 700,

Albany

NY – 12207

United States

Tel: +1-518-618-1030

USA – Canada Toll Free 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com/

Hospital Acquired Disease Testing Market to Benefit from Increasing Infection-related Hospitalization, to Expand at 19.3% CAGR by 2019

Browse Full Article: http://www.transparencymarketresearch.com/article/hospital-acquired-disease-testing.htm

When a patient is hospitalized, their families expect them to get adequate treatment and healthcare facilities. However, the increasing morbidity rate of nosocomial infections presents a completely different picture altogether. Since hospitals are filled with sick people, the chances of getting an infection can drastically increase if proper hygiene is not maintained. Hospital authorities understand and acknowledge the seriousness of the problem. Hence, to combat the rising incidence of hospital acquired diseases, authorities have taken recourse to appropriate testing and diagnostic procedures that can help with the treatment and prevention of the disease.

High Neonatal and Geriatric Population to Drive Global Hospital Acquired Disease Testing Market

High neonatal population in developing countries and increasing geriatric population worldwide are the major factors impacting for global hospital acquired disease testing market. In addition, patients with weak immune system and those exposed to inadequate healthcare conditions are also highly vulnerable to nosocomial infections. Getting in contact with nosocomial infection prolongs the hospital stay of patients, which unduly increases the cost to the patients. To counter the growing prevalence of hospital acquired diseases, many diagnostic tests are introduced in the market, though approximately 70% of the pathogens spreading such infections have become resistant to at least one type of anti-bacterial drug commonly used in nosocomial infection treatment. This has further intensified the challenge for healthcare professionals.

As a potent solution, the healthcare industry has developed a microorganism-specific detection test, which at present is highly in demand from healthcare professionals worldwide for better assessment of disease. Some of the major techniques used in the market today for nosocomial infection diagnosis are PCR, molecular diagnostics, solid phase hybridization, and microarrays. The development of NAT or nucleic acid testing diagnostic products for accurate diagnosis of hospital acquired diseases has paved the way for several players to enter the market.

Make an Enquiry: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1759

Hospital Acquired Disease Testing Market to Grow at 19.3% CAGR

According to a research report by Transparency Market Research, the global hospital acquired disease testing market was valued at US$2.2 billion in 2012 and is projected to be worth US$7.5 billion by 2019. If these estimates by research analysts are justified, the hospital acquired disease testing market is likely to grow at a strong CAGR of 19.3% between 2013 and 2019.

To reduce the high incidence of hospital acquired infections, governments across developed countries such as the U.S., Australia, and Canada, and major economies of Europe have acted to control and prevent the prevalence of nosocomial infections through several inspective and in-house initiatives. Authorities such as the CDC (Centers for Disease Control and Prevention) in the U.S. and National Health and Medical Research Council in Australia have designed rules and recommendation for hospitals and other healthcare institution to manage the numerous types of nosocomial infections.

Asia Pacific to Emerge as a Lucrative Market for HAI Diagnostics

Diagnostic methods such as quantitative PCR, blood culture tests, wound culture, tissue biopsy, and latex agglutination are performed most commonly to diagnose nosocomial infections. HAI diagnostics contributes to 64% of the total molecular diagnostic market. Advent of contemporary diagnostic tools with reduced turnaround time and greater accuracy will further propel the HAI testing market. Asia Pacific is the most lucrative market for HAI testing owing to the high incidence of hospital acquired diseases in countries such as India and China. Geographically, North America dominates the global market for hospital acquired disease testing market at present.

Browse Full Global Hospital Acquired Disease Testing Market Research Report With Complete TOC @ http://www.transparencymarketresearch.com/hospital-acquired-disease-testing.html

Contact us:

Mr. Nachiket
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY – 12207
United States
Tel: +1-518-618-1030
USA – Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

Hospital Acquired Disease Testing Market – Global Industry Analysis, Growth, Trends and Forecast, 2013 – 2019

Transparency Market Research (TMR) has published a new market study based on the global hospital acquired disease testing market. The research report states that the global market will exhibit impressive growth during the forecast period of 2013-2019 at a healthy CAGR of 19.3% and is expected to reach US$7.5 billion by the end of 2019. The market was valued at US$2.2 billion in 2012.The report, titled “Hospital Acquired Disease Testing Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019”, provides an extensive analysis of the global hospital acquired disease testing market. It presents a comparative analysis between the past and present performance of this market and studies the growth prospects for this market in the near future.

Browse Full Press Release: http://www.transparencymarketresearch.com/pressrelease/hospital-acquired-disease-testing.htm

The study states that the rising prevalence of healthcare associated infections (HAIs) and the increasing number of pathogens that are becoming drug resistant is the key factor driving the growth of the hospital acquired disease testing industry across the globe. Further, several governments are implementing code of prevention to keep a check on the increasing prevalence of HAIs. Stringent regulations implemented by regulatory bodies together with the expiring basic PCR patents are expected to fuel the growth of this industry.The report also focuses on analyzing the challenges faced by the global hospital acquired disease testing market such as the shortage of budget and skilled labor as well as control programs and controlling authorities in developing economies. Inflexible regulations and guidance framework implied by various governments are also likely to restrict the global market from growing.

According to this report, the market for urinary tract infection testing leads the infection type based global hospital acquired disease testing market expanding at an 18.1% CAGR during the forecast period. The market for urinary tract infection testing is expected to reach US$2,188.8 million by the end of 2019. The demand for pneumonia testing and surgical site infection (SSI) testing is likely to remain high from developing economies in the Asia Pacific regions.Geographically, the global hospital acquired disease testing market is spread across North America, Europe, Asia Pacific, and the Rest of the World, wherein North America leads the global industry. In 2012, the U.S. and Canada collectively generated around 41% of the total revenue produced by the hospital acquired disease testing market in North America, states the report.

Get Free Sample: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1759

Further, the study reports that the hospital acquired disease testing industry in Asia Pacific is emerging as an attractive market for HAIs testing due its increased prevalence in economies such as India and china. The surging demand to reduce the medical and healthcare expenses by both, patients and healthcare institutions, is another factor propelling the hospital acquired disease testing market in this region.

Browse the full Hospital Acquired Disease Testing Market (Pneumonia, UTI, Blood Stream, Surgical Site, MRSA Infection, and Others) – Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019 report at http://www.transparencymarketresearch.com/hospital-acquired-disease-testing.html

The report also reviews company profiles of the major participants of the global hospital acquired disease testing market such as Abbott Laboratories, Inc., Becton, Dickinson and Co., Alere, Inc., bioMerieux, Inc., Cepheid, Inc., Cantel Medical Corp., Diatherix Laboratories Inc., F. Hoffman-La Roche, Ltd., Gen-Probe, Inc., Life Technologies Corp., Nordion, Inc., Meridian Bioscience, Inc., and Qiagen GmbH. The global industry is highly fragmented having many large and mid-cap enterprises competing with each other.